Welcome to our dedicated page for Astrana Health SEC filings (Ticker: ASTH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Astrana Health's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Astrana Health's regulatory disclosures and financial reporting.
Mazdyasni Matthew reported acquisition or exercise transactions in this Form 4 filing.
Astrana Health director Matthew Mazdyasni received an equity grant. The Form 4 reports an award of 4,525 shares of Astrana Health common stock at no purchase price, granted under the company’s 2024 Equity Incentive Plan.
These restricted shares will vest on the earlier of June 10, 2027 or the date of Astrana Health’s 2027 annual meeting of stockholders. After this grant, Mazdyasni directly owns 39,288 shares of Astrana Health common stock, including the 4,525 unvested restricted shares.
Kitayama Mitchell W reported acquisition or exercise transactions in this Form 4 filing.
Astrana Health, Inc. director Mitchell W. Kitayama received a grant of 4,991 shares of restricted common stock as equity compensation. The award was granted at no cash cost per share under the company’s 2024 Equity Incentive Plan and will vest on the earlier of June 10, 2027 or the company’s 2027 annual meeting of stockholders. Following this grant, Kitayama directly holds a total of 32,837 shares of Astrana Health common stock, including the unvested restricted shares.
Dong Linda reported acquisition or exercise transactions in this Form 4 filing.
Astrana Health, Inc. director Linda Dong received an equity award of 4,525 shares of restricted common stock. The grant was made under the company’s 2024 Equity Incentive Plan. These restricted shares will vest on the earlier of June 10, 2027 or the company’s 2027 annual meeting of stockholders. Following this grant, Dong directly holds 97,133 shares of Astrana Health common stock, including the unvested restricted shares.
Dai, Weili reported acquisition or exercise transactions in this Form 4 filing.
Astrana Health director Weili Dai received a grant of 4,525 shares of restricted common stock under the company’s 2024 Equity Incentive Plan. These shares vest on the earlier of June 10, 2027 or the date of Astrana Health’s 2027 annual stockholders meeting, bringing Dai’s direct holdings to 18,188 shares.
Astrana Health, Inc. reported that director John Chiang acquired 4,525 shares of restricted common stock as a compensation award under the company’s 2024 Equity Incentive Plan. These restricted shares vest on the earlier of June 10, 2027 or the company’s 2027 annual stockholders’ meeting, after which he will fully own them. Following this grant, Chiang directly holds 35,373 shares of Astrana Health common stock.
Astrana Health, Inc. reported results from its 2026 Annual Meeting of Stockholders. Stockholders approved the Amended and Restated 2024 Equity Incentive Plan, which increases the shares of common stock reserved for issuance by 1,000,000 shares and extends the plan’s term until March 24, 2036. All director nominees were elected and the appointment of the independent registered public accounting firm was ratified. An advisory vote on executive compensation passed, and the equity plan received strong support, with 34,679,879 votes in favor. The meeting had a quorum, with 43,772,595 shares represented, about 78.6% of the 55,713,532 shares outstanding as of the record date.
Astrana Health, Inc. COO and CFO Basho Chandan reported a routine share surrender to cover taxes on vested equity. On May 16, 2026, he surrendered 8,155 shares of common stock at an indicated value of $38.26 per share to satisfy tax withholding obligations on restricted stock that vested that day.
After this tax-withholding disposition, Chandan directly owns 159,610 shares of Astrana Health common stock. This total includes 15,202 shares of unvested restricted stock scheduled to vest on May 16, 2027, as well as 15,604 restricted stock units vesting in four equal semi-annual installments beginning October 2, 2026 and 20,027 restricted stock units vesting in six equal semi-annual installments beginning September 5, 2026, all subject to continued employment.
Astrana Health, Inc. disclosed that its Chief Medical Officer, Dinesh Kumar, M.D., has notified the company of his intention to resign. His resignation will be effective June 1, 2026. The company states that Dr. Kumar’s decision is not due to any disagreement with Astrana Health. The filing notes the company’s appreciation for his contributions and extends well wishes for his future endeavors.
Astrana Health, Inc. furnished an updated corporate investor presentation for May 2026. The company plans to use these slides at conferences and meetings, and has attached them as Exhibit 99.1. The material is expressly treated as furnished, not filed, which limits potential securities law liabilities.
The accompanying presentation outlines Astrana’s business mix across Medicare, Medicaid, commercial and other third-party payers, and highlights revenue categories such as capitation, risk pool settlements, management fees and fee-for-service. It also includes a chart of general and administrative expenses and G&A as a percentage of revenue over 2023–2026E.
Astrana Health, Inc. reported strong growth for the quarter ended March 31, 2026, driven by its value-based care model and the 2025 Prospect acquisition. Total revenue rose to $965.1 million, up from $620.4 million a year earlier, with capitation revenue reaching $892.9 million.
Net income attributable to Astrana increased to $14.4 million from $6.7 million, and diluted earnings per share improved to $0.29 from $0.14. Operating income was $28.5 million as higher medical and administrative costs followed the larger network.
Astrana ended the quarter with $478.4 million in cash and cash equivalents and total assets of $2.36 billion, including $874.8 million of goodwill from acquisitions. Long-term debt stood at $1.04 billion, largely from financing the Prospect deal, and medical liabilities were $439.3 million, reflecting obligations under its risk-bearing contracts.